{
  "source": "PA-Regulatory-Ocular-Prophylaxis-for-Gonococcal-Ophthalmia-Neonatorum.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1281-6\nProgram Prior Authorization/Regulatory\nMedication Gonococcal Ophthalmia Neonatorum (GON) Prevention Zero Dollar\nCost Share – erythromycin 0.5% ophthalmic ointment\nP&T Approval Date 5/2019, 5/2020, 2/2022, 4/2023, 5/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nThe U.S. Preventive Services Task Force (USPSTF)1 recommends prophylactic ocular topical\nmedication for all newborns to prevent gonococcal ophthalmia neonatorum (GON). GON can\ncause corneal scarring, ocular perforation, and blindness as early as 24 hours after birth.\nErythromycin ophthalmic ointment is the only FDA approved drug for the prophylaxis of GON.\nOcular prophylaxis of newborns is mandated in most states and is considered standard neonatal\ncare.\nThis program is designed to meet Health Care Reform requirements which require coverage of\n0.5% erythromycin ophthalmic ointment at zero dollar cost share if being used for primary\nprevention of GON.\n2. Coverage Criteria:\nA. Coverage of erythromycin 0.5% ophthalmic ointment at zero dollar cost share will be\napproved based on one of the following criteria:\n1. Member or health care provider intends to administer medication to newborn for the\nprophylaxis of gonococcal ophthalmia neonatorum\n-OR-\n2. Newborn is 0 -1 month of age\nAuthorization will be issued for zero copay with deductible bypass for up to 1 month\nfrom approval.\n3. Additional Clinical Rules:\nN/A\n4. References:\n1. Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum. U.S. Preventive Services Task\nForce https://jamanetwork.com/journals/jama/fullarticle/2722778 Accessed 5/2025\n© 2025 UnitedHealthcare Services Inc.\n1\nProgram Prior Authorization/Regulatory - Gonococcal Ophthalmia Neonatorum\n(GON) Prevention Zero Dollar Cost Share – erythromycin 0.5%\nophthalmic ointment\nChange Control\nDate Change\n5/2019 New program.\n5/2020 Annual review. No changes to coverage criteria.\n2/2022 Annual review. No changes to coverage cri",
    "ost Share – erythromycin 0.5%\nophthalmic ointment\nChange Control\nDate Change\n5/2019 New program.\n5/2020 Annual review. No changes to coverage criteria.\n2/2022 Annual review. No changes to coverage criteria.\n4/2023 Annual review. No changes to coverage criteria.\n5/2024 Annual review. No changes to coverage criteria.\n6/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}